Short- and Long-Term Outcomes of Lung Volume Reduction Surgery
Li Tong,Hou Sheng-cai,Li Hui,Hu Bin,Miao Jin-bai,Zhang Zhen-kui,Wang Yang,Fu Yi-li,You Bin
DOI: https://doi.org/10.1097/00029330-200605010-00012
2006-01-01
Abstract:In 1957, Brantigan1 applied lung volume reduction surgery (LVRS) to the treatment of emphysema. In 1995, Cooper2 reused this operation and obtained remarkable benefit in patients with chronic obstructive pulmonary disease (COPD). Although there are still some doubts about the effect of LVRS, in the past 10 years, a lot of clinical information approved that LVRS can give benefit to more than 70% of COPD patients. At present, a series of researches in long-term investigation and function evaluation such as NETT3 have got elementary affirmative conclusion about some disputative problems. From April 1998 to October 2005, we performed LVRS for 86 cases, and investigated the pulmonary function, symptoms, life quality, and every-year survival rate of the patients which are reported as follows. METHODS Patients (69 men and 17 women) with COPD, aged from 34 to 76 years (63.5 years on average), were included in this study. The indications of LVRS were the same as reported.1–3 The diagnosis of COPD was based on the protocol for diagnosis and treatment norm of COPD.4 Patients' smoking index was 701 in average. The evaluation of the patients' symptoms was based on the dyspnea index of Modified Research Council of Great Britain.5 In our series, 29 patients' dyspnea index were IV, 48 were III and 9 were II. Twenty-five patients needed to inhale oxygen continuously, and 3 of them needed mechanical ventilation support. All patients had barrel chest in physical examination. X-ray showed that the intercostal extent was widen, diaphragm was lower and flat, as well as lung texture was sparse. CT showed that the patients had emphysema, and all of them were heterogeneous. All the patients had target region in ECT (low perfusion and high gas retention). Six-minute walk test (6MWT) was (198± 60) m. Preoperative complication included obsolete tuberculosis in 48.8% of the patients (42/86), spontaneous pneumothorax in 53.5% (46/86, in 36 patients, it occurred for more than 2 times), lung cancer in 2.3% (2/86), and esophageal cancer in 0.1% (1/86). Cardiac arrhythmia happened in 20.9% of the patients (18/86), cardia insufficiency happened in 3.5% (3/86), and hypercapnia in 10.5% (9/86, PaCO255-77 mmHg). We did unilateral LVRS in 61 of the patients. Forty-eight of them underwent video-assisted thoracoscopic surgery (VATS, 31 of them plus minithoracotomy). Thoracotomy was performed for 11 patients, and median incision for 2. Bilateral operation for 25 cases, 21 of which were synchronization operation including 9 VATS (6 of them underwent minithoracotomy), 3 thoracotomy and, 9 median incision; 4 were staging operation including 3 VATS (minithoracotomy), and 1 thoracotomy. We used the endo-GIA, lining-cutter and stapler produced by Tyco healthcare, J & J and Chinese company during the operations, with or without pericardial strips of cattle. The target region which was shown by CT and ECT, and the emphysema region which was looked most destroyed during operation (did not collapse while unilateral ventilation) were cut. The cut volume was about 20%-30% of total lung volume and the cut region was at the peripheral area of the lung. The lung edge was cut in a arc-shape to fill the thorax. Two of these patients (thoracotomy, unilateral LVRS) underwent lobectomy because the lobe was full of bullae, and part of the other lobes' edge was excised. Patients were investigated at 3-72 months after the operation. We surveyed the patients' symptoms, degree of dyspnea, pulmonary functions, blood-gas test, 6MWT and SF-36. Data were expressed as mean±standard deviation (SD) and each group of data was compared with preoperative data by independent-samples t test. P<0.05 was considered statistically significant RESULTS Six patients died within 1 month after LVRS: 4 of them died of respiratory failure (including the patients who needed mechanical ventilation support before operation) and 2 died of bleeding. Forty-five patients got complications and recovered after treatment. The complications included 33 cases of air leaks (>3 days), 22 arrhythmia, 14 respiratory failure, 13 pulmonary infection, 3 empyema of the chest, and 3 pulmonary embolism. Among them, 21 patients had 2 or more than 2 kinds of complications, 4 were reoperated. The other patients recovered without complication. These groups of patients were in hospital from 6 to 102 days after the operation. The air leaked from 0 to 21 days after the operation, 5.3 days in average. The conditions of survival are show in Table 1. The survival rates of 1-6 years were 91.2%, 91.2%, 84.6%, 74.0%, 66.8% and 40.1% respectively (Fig., Tables 2 and 3). Except the dead, the patients' symptoms were alleviated and their capability of movement was increased after the operation. The FEV1, PaO2 and 6MWT were increased, while the TLC, RV and PaCO2 were decreased in comparison with preoperative data. The patients could be selfdependent in life. According to the data of SF-36, patients' life qualities were improved. However, at 36 months the after the operation, their symptoms aggravated, lung function lowered. At 48 months, many of the data were statistically similar to that before the operation. At 60 and 72 months, some data were worse than the preoperative data, without significant difference in statistics.Fig.: Survival rate after operation.Table 1: Survival after lung volume reduction surgeryTable 2: The follow-up data (mean± SD)Table 3: Results of SF-36 investigationsDISCUSSION The viewpoint that patients' dyspnea, quality of life (QOL) and capacity of movement were obviously ameliorated in early-term after LVRS has been accepted wildly. However, long-term outcomes of and LVRS are seldom reported. We began to do LVRS in 1998. Up to now, we have done LVRS for 86 cases, followed up the patients for 6 years. The NETT3 multi-center research indicated that LVRS could increase survival rate and improve life quality markedly. In addition, the patients whose emphysema are more severe in the upper lobe will obtain more benefits. The retrospective analysis about 200 cases of LVRS by Yusen6 showed that in 3 and 5 years after operation, the melioration of dyspnea index were 52% and 40% respectively. This improvement of symptoms and QOL was also found in further random sample researches,7,8 and were much better than that after medical treatment. Our data showed that the patients' symptoms were palliated, most of the patients' dyspnea index was degraded, and some of them achieved degree I. The conditions were much better at 3 and 6 months, aggravated slowly from 12 or 18 months onwards and became similar to the preoperative conditions at 48 months. The influence of LVRS for the long-term survival of COPD patients is now attracting full attention. The non-operative COPD patients' survival rate was much lower than the LVRS patients' survival rate. Brenner9 reviewed 256 LVRS patients, whose 3-year survival rate was 72%. Fujimoto and his colleagues10 observed LVRS of 86 cases, whose 5-year survival rate was 71%. In the research of Ciccone,11 the 1-, 3-and 5-year survival rates were 94%, 84%, and 68% respectively. The report of Meyers12 was more convictive because the patients in medical treatment group had severe emphysema, which is the indication for operation, but were cured by medical treatment. In his research, the 4-year survival rate of operation group was better than medical treatment group obviously (72% vs 41% respectively, P=0.02). NETT showed that the patients with severe emphysema in the upper lobe and low capability in movement gained more advantages, whereas the patients with severe emphysema in the lower lobe and higher capability in movement got worse results. In our series, the 1-6-year survival rates were similar to those reported in documents. The 1- and 2-year survival rates were the same, because no patient died in the second year due to emphysema. These survival rates are better than that of medical treatment group obviously demonstrating that LVRS did change the nature course of emphysema, relieve the condition of COPD and extend the patients' survival time. For these reason, we think that LVRS can improve long-term survival rate of emphysema patients if the the operation is indicated. The data of pulmonary function are not only the important indications for operation but also the chief index of postoperative evaluation. The results of NETT revealed that the data of LVRS were better than medical treatment. In present, a great deal of information showed that after unilateral and bilateral LVRS, the improvement of FEV1 was 25%-35% and 30%-60% respectively, the reduction of RV was 15%-30%. In our group, patients' pulmonary function were ameliorated after operation. FEV1 increased obviously 3 months after operation, reached the highest level at 6 months, reduced slightly at 12 and 18 months and reduced continuously subsequently. The reduction of FEV1 maybe attributes to the development of emphysema and the aggravation of airway obstruction. At 48 months, the difference in FEV1 between post- and preoperative data was still significant. At 60 months, the FEV1 was still higher than preoperative FEV1, but showed significance in statistics. Therefore, the FEV1 fell to preoperative level at 60 months. At 72 months, the FEV1 was lower than preoperative data but the difference was not significant statistically. TLC and RV were reduced after the operation and was significant in comparison with preoperative data. However, the TLC and RV increased gradually. The increase of RV was slightly faster than TLC. The possible reason might be that the gas retention aggravated so that the RV increased and emphysema aggravated. RV and TLC increased to the preoperative level at 48 and 60 months after the operation respectively (by statistical data processing). The data for blood gas ameliorated obviously after the operation, and those for PaO2 raised and PaCO2 reduced. The data reached the best level at 12 months. This is a bit different from the literature which show that it is generally at 6 months when the data reach the best level. LVRS ameliorates pulmonary ventilation function so as to improve the oxygen content and reduce the carbon dioxide content in blood. PaO2 begins to decrease gradually and PaCO2 begins to increase since 12 months. PaO2 can reach the preoperative level at 48 months and PaCO2 at 36 months. Although these data were still a little better than preoperative data at 72 months, the difference was not significant statistically. The increase of PaCO2 was a bit earlier, that might relate to the earlier rise of RV-the higher residual volume might cause the higher volume of CO2. Despite NETT5 put forward doubt to the reliability of 6MWT and proposed that treadmill test should be the gold standard of exercise tolerance, the present 6MWT is still used as the main method for evaluation. Ciccone11 investigated 250 patients for 5 years and found that the operation improved the exercise tolerance by 18% for 1 year and then descended gradually. Five years later, the exercise tolerance reach the preoperative level. In our group, the distance of 6-MWT in postoperative patients increased obviously. From 3 to 36 months after the operation, the data had significant difference in statistics in comparison with preoperative data. The data reached the highest level at 6 months and then descended slowly. The difference was still significant at 60 months and had no significance at 72 months. The reason that the improved time of 6MWT is a bit longer than other data might be related with the patients' adaptation to the low pulmonary function as well as most of the patients did exercises after the operation. Yusen6 reported that the improvement of patients' life quality was 78% and 69% at 3 and 5 years after operation. In our group, patients improved in all of the 8 aspects of SF-36 questionnaire after operation. The bodily pain score decreased and other scores increased. The scores reached the best level at 6 and 12 months and decreased gradually. At 24 months, the scores were still different from preoperative scores in statistics. This illuminate that the improvement of life quality maintained at least more than 2 years. At 36 months, the social functioning, vitality, and bodily pain had decreased or increased to the preoperative level (no difference in statistics). Physical functioning and role physical were still higher than preoperative scores and the other reached the preoperative level at 48 months. At 60 months, only physical functioning was higher than the preoperative score. All of the scores showed no difference from that before the operation in statistics at 72 months. In the data of our group, the scores of physical functioning and role physical dropped lately. We think that the improvement of SF-36 is due to the improvement of pulmonary function as well as the improvement of movement capacity. In addition, the improvement of pulmonary function leads to the improvement of oxygenation level and ameliorates other organs' physical function. In conclusion, LVRS can improve the survival rate of COPD patients, ameliorate pulmonary function, palliate symptom and increase life quality in short-and long-term after operation. However, the conditions of every aspect drop to preoperative level at about 5 years after operation.